ABO-Incompatible Kidney Transplant at KIMS Secunderabad — Blood Group Mismatch Is Not the End of the Road
At a glance — ABO-Incompatible Transplant at KIMS
- The central message: A blood group mismatch between donor and recipient does NOT automatically exclude kidney transplant. KIMS performs ABO-incompatible (ABOi) kidney transplants through a structured desensitisation protocol.
- The barrier being overcome: Naturally occurring anti-A and anti-B antibodies (isoagglutinins) mount an immediate rejection response against incompatible blood group antigens on the transplanted kidney. The desensitisation protocol reduces these antibodies to a safe level before surgery.
- How KIMS overcomes it: Rituximab infusion to deplete the B-cells producing anti-A/B antibodies · Plasmapheresis sessions to physically remove circulating antibodies · Isoagglutinin titre monitoring to confirm safety threshold before surgery
- Outcomes: 1-year graft survival 90–95% at experienced centres — approaching compatible transplant outcomes
- Experience base: Over 1,500 total kidney transplants at KIMS — volume that makes complex desensitisation protocols safe and outcomes predictable
- Alternative: Paired kidney exchange (swap transplant) — also available at KIMS for eligible incompatible pairs
- Appointments: 040 - 44885000 · assistance@kimshospitals.com
Why blood group mismatch used to mean no transplant — and why that changed
In the early decades of kidney transplantation, ABO blood group compatibility was considered an absolute requirement. Every person naturally carries antibodies against the blood group antigens they do not possess — an O-group recipient carries anti-A and anti-B antibodies; an A-group recipient carries anti-B; a B-group recipient carries anti-A; only AB recipients carry neither. When a kidney from an incompatible donor is transplanted, these antibodies attack the blood vessel cells of the new kidney — triggering hyperacute rejection within minutes to hours of reperfusion, destroying the kidney before the patient leaves the operating table.
The breakthrough came from understanding that if the antibody burden could be reduced to a safe level before surgery through a structured desensitisation protocol, the transplanted kidney would survive even across a blood group mismatch. Through a combination of rituximab (to stop antibody production) and plasmapheresis (to remove existing antibodies), the recipient's immune system is temporarily modified — allowing the incompatible kidney to be transplanted successfully. The transplanted kidney then undergoes accommodation: its blood vessel cells adapt to the residual antibodies, achieving tolerance. At experienced centres, ABO-incompatible transplant 1-year graft survival now approaches 90 to 95% — comparable to compatible transplant outcomes.
If you have been told that your willing kidney donor has a mismatched blood group and transplant is therefore not possible — this needs to be reviewed by the KIMS transplant team. Depending on your specific blood group combination and your starting antibody levels, ABO-incompatible transplant may be entirely feasible at KIMS. A blood group mismatch is a clinical challenge to be assessed — not an automatic disqualification. Call 040 - 44885000.
The KIMS ABO-incompatible desensitisation protocol — step by step
| Protocol stage | What happens and why |
|---|---|
| 1 — Isoagglutinin titre baseline | Blood sample from the recipient tests anti-A and anti-B IgG and IgM antibody titres. This establishes the starting titre and determines how many plasmapheresis sessions will likely be needed. Very high starting titres (above 1:512) occasionally indicate that ABOi transplant is not feasible for that pair. |
| 2 — Rituximab infusion (Day -21 to -30) | A single infusion of rituximab — a monoclonal antibody depleting CD20-positive B lymphocytes — is given 3 to 4 weeks before the planned transplant. B-cells produce the anti-A and anti-B antibodies. Depleting them prevents antibody regeneration after plasmapheresis, allowing the titre to remain low once reduced. |
| 3 — Plasmapheresis sessions (Day -14 to -1) | Plasmapheresis removes antibodies physically — the blood is processed through a separator, plasma (containing the antibodies) is removed and replaced with albumin or fresh frozen plasma. Each session reduces the titre by approximately 50%. Sessions are performed every other day over 2 weeks. Titre is checked after every 2 sessions to track progress toward the target threshold (typically anti-A and anti-B IgG below 1:8). |
| 4 — Titre target and transplant scheduling | When the titre reaches the safety threshold, the transplant is scheduled within 24 to 48 hours — before the titre rebounds. The final pre-operative titre is measured on the morning of surgery. If the titre has risen above the threshold overnight, an additional plasmapheresis session is performed before proceeding. |
| 5 — Transplant surgery | Standard kidney transplant surgery — identical in technique and duration to compatible transplant. Class-100 Laminar Flow OT at KIMS. The kidney is reperfused and immediately assessed for function. |
| 6 — Post-transplant titre monitoring | Isoagglutinin titres measured daily for 5 to 7 days post-transplant — the period of highest rebound risk. If the titre rises above the safe level, additional plasmapheresis is performed immediately. Standard triple immunosuppression (tacrolimus + MMF + prednisolone) maintains immune suppression. |
| 7 — Accommodation and long-term follow-up | Over weeks to months, the transplanted kidney undergoes accommodation — the endothelial cells adapt to the residual low-level antibodies, achieving functional tolerance. Titres stabilise at a low level. Standard monthly post-transplant nephrology review continues indefinitely. |
Which blood group combinations are managed with ABOi transplant?
| Blood group combination (Recipient + Donor) | Antibodies to overcome · Feasibility |
|---|---|
| O recipient + A donor | Anti-A antibodies to be desensitised. High starting titres common in O-group recipients — most demanding desensitisation. Feasible in most cases. |
| O recipient + B donor | Anti-B antibodies to be desensitised. Similarly demanding to O+A. Feasible in most cases. |
| O recipient + AB donor | Both anti-A and anti-B to be desensitised simultaneously. Most complex combination — feasibility assessed individually at KIMS. |
| A recipient + B donor | Anti-B antibodies to be desensitised. Starting titres typically lower than O-group recipients — often more manageable desensitisation course. |
| B recipient + A donor | Anti-A antibodies to be desensitised. Similar to A+B in complexity and feasibility. |
| AB recipient | No anti-A or anti-B antibodies — AB recipients are universal recipients and do not require ABOi desensitisation. Compatible with any donor. |
The feasibility of ABO-incompatible transplant for any specific pair depends on the starting isoagglutinin titre — not simply the blood group combination. Two O-group recipients facing A-group donors may have entirely different starting titres and very different desensitisation requirements. A single KIMS evaluation appointment determines feasibility for each specific pair.
Outcomes — ABOi transplant vs compatible transplant vs dialysis
The relevant clinical comparison for a patient considering ABO-incompatible transplant is not primarily ABOi transplant vs compatible transplant — it is ABOi transplant vs remaining on dialysis indefinitely without a compatible donor. When framed correctly, the case for ABOi transplant where a willing incompatible donor is available is compelling:
| Outcome | ABOi transplant | Compatible transplant | Dialysis |
|---|---|---|---|
| 1-year graft survival | ABOi: 90–95% at experienced centres | Compatible: 92–97% | Not applicable |
| 5-year graft survival | ABOi: 80–85% | Compatible: 82–88% | Not applicable |
| 5-year patient survival | ABOi: Substantially better than dialysis | Better than dialysis | Significantly worse than transplant |
| Quality of life | ABOi: Freedom from dialysis — transformative | Freedom from dialysis | 3 sessions per week, restrictions indefinitely |
| Time to treatment | ABOi: 4–6 weeks for desensitisation then surgery | Immediate (if donor available) | Indefinite wait for compatible deceased donor |
| Cost | ABOi: Higher than compatible (rituximab + plasmapheresis premium) | Standard transplant cost | Cumulative over years — exceeds transplant within 3–5 years |
Paired kidney exchange — the alternative to consider first
For some ABO-incompatible pairs, paired kidney exchange (swap transplant) offers an alternative to desensitisation. Two incompatible donor-recipient pairs exchange donors to achieve two compatible transplants simultaneously. The classic example: Recipient A (blood group O) has willing Donor 1 (blood group B). Recipient B (blood group B) has willing Donor 2 (blood group O). If Donor 2 is compatible with Recipient A, and Donor 1 is compatible with Recipient B, the pairs swap — both transplants proceed simultaneously as compatible transplants, without any desensitisation.
KIMS assesses both ABOi desensitisation and paired kidney exchange suitability for every incompatible pair at the initial evaluation. Where a swap partner is available through the TSTA-approved paired exchange programme, swap transplant avoids the rituximab and plasmapheresis cost and complexity entirely.
Why choose KIMS Secunderabad for ABO-incompatible kidney transplant?
1,500+ total kidney transplants
The experience base that makes ABOi safe. ABO-incompatible transplant is demanding in pre-operative management: the interpretation of titre trends and the critical decision of when the titre is low enough to proceed safely require a transplant team with deep experience. KIMS has one of South India's highest volumes providing the accumulated expertise for these complex judgements.
Same nephrology team throughout
The KIMS nephrologist who measures the initial isoagglutinin titre manages the rituximab infusion, supervises the plasmapheresis schedule, monitors titre trends, clears the patient for surgery, checks titres daily in the post-transplant period, and manages long-term immunosuppression. No handover at any stage.
TSTA empanelled & full legal compliance
All ABO-incompatible transplants at KIMS are conducted under TSTA (Telangana State Transplant Authority) compliance, with the required ethics committee review for each case. The KIMS transplant coordinator manages all TSTA documentation — the patient and donor family are guided through the process.
Paired exchange assessed for every pair
Before recommending ABOi desensitisation, KIMS assesses whether paired kidney exchange is available through the TSTA programme — swap transplant avoids the cost and desensitisation burden where a suitable cross-compatible pair exists. The recommendation is individualised, not a fixed protocol.
Our ABO-incompatible transplant team at KIMS Secunderabad
Frequently Asked Questions
Not necessarily. ABO-incompatible kidney transplantation is an established procedure at experienced transplant centres. KIMS performs ABO-incompatible transplants through a structured protocol: rituximab to deplete the B-cells producing the mismatched antibodies, followed by plasmapheresis to remove the circulating antibodies, and isoagglutinin titre monitoring to confirm the antibody level has reached a safe threshold before surgery. Feasibility depends on your specific blood group combination and your starting antibody titre — a single evaluation appointment at KIMS determines whether ABOi transplant is an option for your specific pair. Call 040 - 44885000 to arrange this assessment. A blood group mismatch is a challenge to be assessed, not an automatic disqualification.
Isoagglutinins are the naturally occurring anti-A and anti-B antibodies everyone carries against blood group antigens they do not possess. An isoagglutinin titre measures the concentration of these antibodies — expressed as the highest dilution at which the antibody is still detectable. For example, a titre of 1:64 means the antibody is detectable even at 64-fold dilution. A high starting titre means more plasmapheresis sessions are needed to reach the pre-transplant target (typically below 1:8 for most combinations) and is associated with higher rebound risk after transplant. A lower starting titre responds more readily to desensitisation.
This depends on your starting isoagglutinin titre and the rate of decline with each session. Each plasmapheresis session reduces the titre by approximately 50%. Starting from 1:64 to reach the target of 1:8 typically requires 3 to 4 sessions. Starting from 1:256 may require 6 to 8 sessions. Sessions are performed every other day over approximately 2 weeks. After every 2 sessions, the titre is measured. When the target is reached, the transplant is scheduled within 24 to 48 hours. If the titre has partially rebounded by the morning of surgery, one additional plasmapheresis session is performed before proceeding. Most patients complete the desensitisation protocol and proceed to transplant within 4 to 6 weeks of starting the programme.
At experienced high-volume transplant centres, ABO-incompatible kidney transplant achieves 1-year graft survival of 90 to 95% — approaching the 92 to 97% seen with compatible transplants. Five-year graft survival is 80 to 85% for ABOi vs 82 to 88% for compatible. The critical comparison for most patients is not ABOi vs compatible — it is ABOi transplant vs remaining on dialysis indefinitely while waiting for a compatible deceased donor. ABOi transplant confers the same transformative survival and quality-of-life advantage over long-term dialysis as compatible transplant. The few percentage points of difference in graft survival between ABOi and compatible transplant is clinically meaningful, but it does not change the fundamental value proposition: a willing incompatible donor now is substantially better than waiting years for a compatible deceased donor.
Both are solutions for incompatible donor-recipient pairs, but they work through completely different mechanisms. ABO-incompatible transplant modifies the recipient through rituximab and plasmapheresis to allow the incompatible donor to give directly. Swap transplant (paired kidney exchange) avoids desensitisation entirely — it identifies another incompatible pair who happen to be cross-compatible with each other, and both pairs exchange donors so that each transplant proceeds as a compatible transplant. Where a swap partner exists, swap transplant is preferred because it avoids the rituximab and plasmapheresis cost and complexity. Where no suitable swap partner is available, ABOi desensitisation is offered. KIMS assesses both options for every incompatible pair at the initial evaluation.
Yes. The donor surgery in ABO-incompatible transplant is identical to compatible live donor surgery — laparoscopic donor nephrectomy under general anaesthesia, 1 to 2 nights in hospital, return to normal activity within 2 to 4 weeks. The rituximab infusion and plasmapheresis sessions are given to the recipient only — the donor receives no additional medications or procedures related to the blood group mismatch. The donor undergoes the same full medical, psychological, and TSTA ethical evaluation as for any live kidney donation. The blood group mismatch between donor and recipient creates no additional surgical or medical risk for the donor.
Yes — through a process called accommodation, the transplanted kidney adapts to its new environment over weeks to months. The blood vessel cells lining the donor kidney undergo protective changes that make them tolerant to the residual low-level anti-A or anti-B antibodies still present in the recipient after desensitisation. This accommodation, combined with standard triple immunosuppression (tacrolimus, mycophenolate mofetil, prednisolone), allows ABOi transplanted kidneys to function long-term. Isoagglutinin titres are monitored post-transplant and stabilise at a low baseline in most patients. Long-term graft function and patient survival in ABOi transplant are determined primarily by the quality of immunosuppression management — exactly as with compatible transplant.
KIMS Secunderabad — over 1,500 total kidney transplants providing the experience base for safe and effective desensitisation protocols, full ABOi programme including rituximab infusion and plasmapheresis, isoagglutinin titre monitoring throughout, same nephrology team managing every stage from evaluation to lifelong post-transplant immunosuppression, TSTA empanelled for full legal compliance, paired kidney exchange assessed as alternative for every incompatible pair. NABH and NABL accredited. Times Healthcare Achievers — Best Hospital of the Year in Nephrology.